DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Adenocarcinoma of Stomach; Adenocarcinoma of GE Junction; Adenocarcinoma of Esophagus

Intervention: Doxorubicin (Drug); Cisplatin (Drug); 5-fluorouracil (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Dana-Farber Cancer Institute

Official(s) and/or principal investigator(s):
Matthew Kulke, MD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute


The purpose of this study is to collect information on the anti-tumor activity of the combination doxorubicin, cisplatin, and 5-fluorouracil when given to patients with advanced esophageal or gastric adenocarcinoma. We will also be collecting information about the side effects and safety of this combination.

Clinical Details

Official title: A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To determine the activity of doxorubicin, cisplatin and continuous infusion of 5-fluorouracil in patients with measurable, locally unresectable or metastatic adenocarcinoma of the stomach, GE junction, or esophagus.

Secondary outcome:

Assess the safety of doxorubicin, cisplatin and 5-fluorouracil when given in combination to treat this patient population

evaluate the survival of this patient population.

Detailed description:

- Patients will receive cisplatin and doxorubicin intravenously once every 3 weeks. In

addition to cisplatin and doxorubicin, patients will receive 5-fluorouracil intravenously as a continuous infusion for the duration of the study. In order to do this, patients will receive an infusion pump that can be carried with them. Treatment cycles will be repeated every 21 days for a maximum of 8 cycles.

- Prior to enrollment in this study and while the patient is receiving the therapy,

routine blood tests and x-ryas (including chest x-rays and CT scans) will be performed to check the body's response to the treatment. Blood tests will be checked once a week and chest x-rays and CT scans will be checked every 6 weeks.

- Patients with progressive disease or intolerable side effects will be removed from the

study. Patients with stable disease or tumor response will continue therapy for a maximum of 8 cycles.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Measurable, locally unresectable or metastatic adenocarcinoma of the stomach, GE

junction or esophagus

- No more than one prior chemotherapy regimen

- ECOG performance status of < or equal to 2

- Life expectancy > 12 weeks

- ANC > 1,500/mm3

- Hemoglobin > 9. 0 gm/dl

- Platelets > 100,000/mm3

- SGOT < 3 x ULN

- Total bilirubin < 2. 0 mg/dl

- Creatinine < 1. 5 mg/dl

Exclusion Criteria:

- Prior cisplatin or doxorubicin as neoadjuvant or adjuvant therapy with in 1 year of

study entry

- Clinically apparent central nervous system metastases or carcinomatous meningitis

- Myocardial infarction in the past 6 months

- Major surgery in the past 2 weeks

- Uncontrolled serious medical or psychiatric illness

- Pregnant or lactating women

- Concurrent malignancy of any site, except limited basal cell carcinoma or squamous

cell carcinoma of the skin or carcinoma in situ of the cervix

- History or clinical evidence of congestive heart failure

Locations and Contacts

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States

Massachusetts General Hospital, Boston, Massachusetts 02115, United States

Additional Information

Starting date: August 1998
Last updated: April 27, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017